Animal Antibiotics and Antimicrobials Market growth can largely be attributed to the rising demand for animal-derived food products, the increasing incidence of zoonotic diseases, and the implementation of regulations to prevent the spread of animal diseases. Rising animal healthcare spending and the growing demand for pet insurance are further expected to drive the growth of this market. The untapped emerging markets such as China, India, and Brazil and growth in the overall companion animal population are also expected to offer significant growth opportunities to market players in the coming years.
Currently, Animal Antibiotics and Antimicrobials Market is growing at a Compound Annual Growth Rate (CAGR) of 3.6 % to reach USD 5.6 billion by 2026. The global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products. In 2020, the tetracyclines segment accounted for 48.9% of the global animal antimicrobials and antibiotics market. Tetracyclines exhibit advantages such as the highest potency against pathogenic microorganisms, being well-absorbed, showing low toxicity, and being relatively inexpensive compared to other animals antimicrobial and antibiotic products. These advantages contribute to the large share of this product segment. The fluoroquinolones segment is expected to grow at the highest CAGR of 8.0% during the forecast period. Advantages such as higher efficacy at low concentrations, quick penetration through tissues, and the availability of variations in the route of administration result in the higher adoption of fluoroquinolones among end users.
Request for assumptions & how numbers were triangulated.
https://www.marketsandmarkets.com/requestsampleNew.asp?id=25161353
Growth Drivers
- Rising demand for animal-derived food products
- Increasing incidence of zoonotic diseases
- Increasing investments from private players
- Rising demand for pet insurance and growing animal health expenditure
Growth Opportunities
- Untapped emerging markets
- Growth in the companion animal population
Challenges
- Stringent approval process for antimicrobials and antibiotics
Trends
- Growing consolidation in the animal health industry
- Growing focus on limiting the use of antibiotics in livestock animals
- High growth in emerging markets
The prominent players operating in the Animal Antibiotics and Antimicrobials Market are
Zoetis Inc. (US), Elanco Animal Health (US), Merck & Co. Inc (US), Phibro Animal Health (US), Virbac (France), and Vetoquinol S.A. (France)
Zoetis accounted for the largest share of the animal antimicrobials and antibiotics market in 2020. The company provides highly diversified products for a wide range of animal species. The company’s broad geographic diversity has enabled it to deliver its animal healthcare products to more than 110 countries worldwide. To maintain its position in the animal antimicrobials and antibiotics market, the company focuses on providing innovative products, building a strong geographical network, and enhancing its R&D capabilities to deliver measurable and beneficial results for animals.
Merck accounted for second largest of the market in 2020. The company’s strong focus on a broad range of animals, investments in collaborations & partnerships, and comprehensive quality systems and processes are driving its growth in the market. It focuses on acquisitions, expansions, and collaborations, as well as product launches. In March 2017, Merck Animal Health (known as MSD Animal Health in the US and Canada) acquired Vallée S.A., a leading privately-held producer of animal health products in Brazil. This helped Merck offer a comprehensive portfolio of products for livestock animals and expand its reach in Latin America.
Download an Illustrative Overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=25161353
North America is expected to exhibit the highest growth during the forecast period
- The increase in the region’s animal population
- Rising demand for animal-derived food products
- Growth in pet insurance and rising animal health expenditure compared to other regions.
Recent Developments
- In 2020, Zoetis (US) acquired entered into an agreement with Trianni Inc. (US) to develop transgenic monoclonal antibody platforms for the discovery of new veterinary treatments
- In 2020, Zoetis (US) received FDA approval for Marboquin
- In 2019, Elanco (US) collaborated with AgBiome to develop nutritional health products for porcine animals.
- In 2019, Elanco Animal Health (US) Announced the acquisition of Bayer’s Animal Health Business, thereby expanding its own companion animal business and portfolio mix by creating a balance between its food animal and companion animal segments
- In 2019, Boehringer Ingelheim (Germany) acquired Sanofi’s Animal Health business (Merial), and Sanofi took over Boehringer Ingelheim’s Consumer Healthcare (CHC) business. The acquisition of Merial made BI the world’s second-largest animal health company
